Capital Advisors Inc. OK Has $59.53 Million Position in AbbVie Inc. (NYSE:ABBV)

Capital Advisors Inc. OK boosted its position in AbbVie Inc. (NYSE:ABBV) by 1.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 335,011 shares of the company’s stock after buying an additional 5,119 shares during the period. AbbVie makes up approximately 1.2% of Capital Advisors Inc. OK’s portfolio, making the stock its 22nd biggest position. Capital Advisors Inc. OK’s holdings in AbbVie were worth $59,531,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ABBV. AMF Tjanstepension AB bought a new position in shares of AbbVie during the third quarter valued at about $8,777,000. Redhawk Wealth Advisors Inc. lifted its holdings in AbbVie by 3.1% in the third quarter. Redhawk Wealth Advisors Inc. now owns 2,609 shares of the company’s stock worth $515,000 after buying an additional 78 shares during the period. Grove Bank & Trust increased its stake in shares of AbbVie by 1.2% during the third quarter. Grove Bank & Trust now owns 12,859 shares of the company’s stock valued at $2,539,000 after purchasing an additional 149 shares in the last quarter. Sivia Capital Partners LLC increased its stake in shares of AbbVie by 2.2% during the third quarter. Sivia Capital Partners LLC now owns 4,493 shares of the company’s stock valued at $887,000 after purchasing an additional 98 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. bought a new position in shares of AbbVie during the third quarter valued at approximately $46,000. 70.23% of the stock is owned by institutional investors.

Insider Activity at AbbVie

In other news, SVP Kevin K. Buckbee sold 1,800 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the completion of the transaction, the senior vice president now directly owns 6,983 shares of the company’s stock, valued at $1,202,751.92. This trade represents a 20.49 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.25% of the stock is currently owned by corporate insiders.

AbbVie Trading Up 0.8 %

Shares of ABBV stock opened at $191.81 on Wednesday. The firm has a fifty day moving average of $177.71 and a 200-day moving average of $185.81. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65. AbbVie Inc. has a 52-week low of $153.58 and a 52-week high of $207.32. The stock has a market cap of $338.96 billion, a price-to-earnings ratio of 79.92, a P/E/G ratio of 1.53 and a beta of 0.58.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same quarter in the prior year, the business posted $2.79 EPS. On average, equities research analysts forecast that AbbVie Inc. will post 12.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on ABBV shares. UBS Group boosted their target price on shares of AbbVie from $181.00 to $190.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Wolfe Research assumed coverage on shares of AbbVie in a report on Friday, November 15th. They issued an “outperform” rating and a $205.00 target price for the company. Leerink Partnrs raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Friday, November 22nd. Morgan Stanley increased their price objective on shares of AbbVie from $224.00 to $239.00 and gave the company an “overweight” rating in a report on Monday, February 3rd. Finally, Piper Sandler upped their target price on shares of AbbVie from $212.00 to $220.00 and gave the company an “overweight” rating in a research report on Tuesday, December 17th. Five analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $208.35.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.